US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
22/06/2026 13:35
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug June 22 (Reuters) - The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' ACHV.O drug to treat nicotine dependence in adults, the company said on Monday.
(Reporting by Kunal Das in Bengaluru; Editing by Diti Pujara)
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock